Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958486 · ClinicalTrials.gov registry record · Early Phase 1
Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa Ependymoma
A Early Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT04958486 is a Early Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 4 participants.
The verdict
NCT04958486, a Early Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safety and tolerability of simultaneous infusions of 5-Azacytidine and trastuzumab into the fourth ventricle of the brain or resection cavity in patients with recurrent posterior fossa ependymoma and to assess the antitumor activity of simultaneous infusions of 5-Azacytidine and trastuzumab into the fourth ventricle of the brain or resection cavity in patients based upon imaging studies and lumbar cerebrospinal fluid (CSF) cytology.
Interventions
- DRUG 5-Azacytidine and trastuzumab infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-07-08 |
| Est. Completion | 2023-09-29 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04958486
The ClinicalTrials.gov registry entry for NCT04958486 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 5-Azacytidine and trastuzumab infusion is the first listed.
NCT04958486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04958486 about?
NCT04958486 is a clinical study titled "Combination Intraventricular Chemotherapy Pilot Study: 5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle or Resection Cavity in Children and Adults with Recurrent or Residual Posterior Fossa Ependymoma". The purpose of this study is to establish the safety and tolerability of simultaneous infusions of 5-Azacytidine and trastuzumab into the fourth ventricle of the brain or resection cavity in patients with recurrent posterior fossa ependymoma and to assess the antitumor activity of simultaneous infus...
What is the current status of trial NCT04958486?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2021-07-08. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT04958486?
The interventions under investigation include: 5-Azacytidine and trastuzumab infusion (DRUG).
Who is sponsoring clinical trial NCT04958486?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.